KINETO Lab Ltd.

Csillaghegyi út 19-21.
H-1037 Budapest,Hungary

Phone: + 36 20 914 6882

info@kinetolab.hu

www.kinetolab.hu

KINETO Lab Ltd. is a privately owned Hungarian biotech research company founded by two biologist and one chemist in 2007 for testing and developing new antitumoral compounds. KINETO Lab currently employs 3 people in R&D professional. Chartered laboratory of KINETO Lab is fully equipped with instruments for in vitro cell-based analysis and for molecular techniques as well. KINETO Lab develops different methods for testing the possible effect of new agents on tumor cell migration, adhesion, matrix interaction, proliferation and programmed cell death (apoptosis).

KINETO Lab has special expertise for testing these agents in different in vivo human tumor xenograft models (i.e. subcutaneous tumor growth, intracardial and intravenous inoculation, spleen-liver metastasis model etc).

The principal investigator on behalf of KINETOLab Ltd. is Dr. József Tóvári. Dr. Tóvári is principal investigator of several basic research and R&D projects in the field of tumor progression:
„Mechanism and regulation of human tumor cell motility" research grant, National Science Foundation (OTKA F046501); principal investigator; 2004-2007
„Innovative development in cancer therapy using genomic approach" Jedlik Á. Programme (NKFP1-00024/2004) R&D grant, co-investigator, 2004-2008.
"Comprehensive preclinical investigation of drugs with inhibitory potential for the Ras signaling pathway in human malignancies" R&D grant, co-investigator, 2009-20012.
Developing of new diagnostic methods for the detection of circulating endothelial progenitor cells (INNO_08-3-2009-0024):
- CD34 and VEGFR2 antibodies
PCT: „Microchannel-based cell capture device for the analysis of cellular content of samples", no. Ep14168842.
Peptide-Drug Conjugates for Targeted Delivery in Tumor Therapy (MAGICBULLET, H2020) Industrial partners: Bayer Pharma AG (DE), Heidelberg Pharma GmbH (DE), Exiris (IT)

These techniques can be useful for detecting the possible effect of newly synthesized agents on tumor progression in preclinical investigation phase.